Analyst firms · Oppenheimer · INCY

Oppenheimer INCY price target and rating history

Incyte Corp. (INCY) · Health Care

Oppenheimer rates Incyte Corp. (INCY) Outperform with a $144 price target, as of its latest action on Oct 30, 2026. It has published 3 rating actions on INCY since November 2021, including 1 upgrade and 1 downgrade. Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Oppenheimer's $144 is 21% above that.

Current rating
Outperform
Price target
$144
Median target, all firms
$119
Actions on INCY
3

Oppenheimer price target on INCY

$144$127$10920222023202420252026
Oppenheimer price target on INCY, each point a stated target, November 2021 to October 2026.

Every Oppenheimer rating on INCY

How other firms rate INCY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$144Oct 30, 2026
Morgan StanleyEqual-Weight$119Oct 20, 2026
Canaccord GenuityBuy$152Aug 20, 2026
BMO Capital MarketsMarket Perform$94Jun 22, 2026
BernsteinMkt Perform$99May 22, 2026
JefferiesHold$94Mar 16, 2026
H.C. WainwrightBuy$135Feb 5, 2026
Wells FargoEqual Weight$107Jan 20, 2026
MizuhoOutperform$121Dec 8, 2025

Questions about Oppenheimer and INCY

What is Oppenheimer's price target for INCY?
Oppenheimer's latest stated price target for Incyte Corp. (INCY) is $144, from its action on Oct 30, 2026.
What is Oppenheimer's rating on INCY?
Oppenheimer rates INCY Outperform, a bullish rating, as of Oct 30, 2026.
When did Oppenheimer last change its view on INCY?
On Oct 30, 2026, Oppenheimer upgrades to Outperform from Perform, price target $144.
How does Oppenheimer's INCY target compare with other analysts?
Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Oppenheimer's $144 is 21% above that.

More INCY rating histories

All Oppenheimer ratingsINCY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.